NEW YORK - Immunocore yati Lolemba igulitsa magawo 3,733,333 mu mgwirizano wa ndalama za private equity investment (PIPE) womwe ukuyembekezeka kupeza $140 miliyoni.
Pansi pa mgwirizanowu, Immunocore idzagulitsa masheya ake wamba ndi masheya wamba omwe savoteredwa pa $37.50 pa gawo lililonse. Omwe ayika ndalama mu kampaniyo omwe akutenga nawo gawo mu ndalamazi ndi RTW Investments, Rock Springs Capital ndi General Atlantic. Pangano la PIPE likuyembekezeka kutha pa Julayi 20.
Kampaniyo idzagwiritsa ntchito ndalama zomwe zapezeka pothandizira odwala khansa komanso matenda opatsirana, kuphatikizapo kupanga katswiri wawo wamkulu wa khansa, Kimmtrak (tebentafusp-tebn), pochiza matenda a khungu a HLA-A*02:01 komanso khansa ya uveal. Ndalamazi, pamodzi ndi ndalama zomwe Kimmtrak amapeza, zikuyembekezeka kulipira ntchito za Immunocore mpaka chaka cha 2025.
Chaka chino, Kimmtrak yavomerezedwa kuti igwiritsidwe ntchito kwa odwala omwe ali ndi melanoma ya HLA-A*02:01 yomwe singathe kuchiritsidwa kapena yofalikira ku US, Europe ndi UK, pakati pa mayiko ena. Immunocore ikupitiliza kuphunzira mankhwalawa mu kafukufuku wa Phase I/II mu melanoma ya khungu ya HLA-A*02:01 yomwe ili ndi khansa.
Immunocore ikupanganso mankhwala ena anayi ofunikira pa khansa, kuphatikizapo mankhwala ena awiri owonjezera a T-cell receptor mu mayeso a Gawo I/II mu zotupa zolimba kwambiri. Limodzi mwa mankhwalawa likupangidwira odwala omwe ali ndi HLA-A*02:01-positive ndi MAGE-A4-positive, ndipo lina likulunjika ku zotupa za HLA-A*02:01 ndi PRAME-positive. Kampaniyo ilinso ndi odwala awiri osadziwika omwe ali ndi khansa omwe akukonzekera chitukuko cha preclinical.
Ndondomeko Yachinsinsi. Malamulo ndi Zikhalidwe. Copyright © 2022 GenomeWeb, gawo la bizinesi la Crain Communications. ufulu wonse ndi wotetezedwa.